"The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are"...
Cefuroxime Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Cefuroxime and dextrose injection is an antibacterial used to treat lower respiratory tract infections, urinary tract infections, skin infections, septicemia, meningitis, gonorrhea and bone and joint infections. It is available in generic form. Common side effects of cefuroxime and dextrose are inflammation at the site of injection, diarrhea, watery or bloody stools, stomach cramps, and fever.
The recommended dosage of cefuroxime and dextrose is 750 mg to 1.5 grams every 8 hours for 5 to 10 days. Benedict's solution, Fehling's solution and Clinitest tablets may interact with cefuroxime and dextrose. Tell your doctor all medications you take. Only use cefuroxime and dextrose to treat bacterial infections. It is not an effective treatment for viral infections such as the common cold. Do not skip doses or stop taking cefuroxime and dextrose earlier than directed even if you feel better. Only use cefuroxime and dextrose during pregnancy if clearly needed. Exercise caution if using cefuroxime and dextrose while breastfeeding.
Our Cefuroxime and Dextrose Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Cefuroxime FDA Prescribing Information: Side Effects
Cefuroxime (cefuroxime (cefuroxime injection) injection) is generally well tolerated. The most common adverse effects have been local reactions following IV administration. Other adverse reactions have been encountered only rarely.
Local Reactions: Thrombophlebitis has occurred with IV administration in 1 in 60 patients.
Gastrointestinal: Gastrointestinal symptoms occurred in 1 in 150 patients and included diarrhea (1 in 220 patients) and nausea (1 in 440 patients). The onset of pseudomembranous colitis may occur during or after antibacterial treatment (see WARNINGS).
Hypersensitivity Reactions: Hypersensitivity reactions have been reported in fewer than 1% of the patients treated with cefuroxime (cefuroxime (cefuroxime injection) injection) and include rash (1 in 125). Pruritus, urticaria, and positive Coombs' test each occurred in fewer than 1 in 250 patients, and, as with other cephalosporins, rare cases of anaphylaxis, drug fever, erythema multiforme, interstitial nephritis, toxic epidermal necrolysis, and Stevens-Johnson syndrome have occurred.
Blood: A decrease in hemoglobin and hematocrit has been observed in 1 in 10 patients and transient eosinophilia in 1 in 14 patients. Less common reactions seen were transient neutropenia (fewer than 1 in 100 patients) and leukopenia (1 in 750 patients). A similar pattern and incidence were seen with other cephalosporins used in controlled studies. As with other cephalosporins, there have been rare reports of thrombocytopenia.
Kidney: Elevations in serum creatinine and/or blood urea nitrogen and a decreased creatinine clearance have been observed, but their relationship to cefuroxime (cefuroxime (cefuroxime injection) injection) is unknown.
Postmarketing Experience with Cefuroxime (cefuroxime (cefuroxime injection) injection) : In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with cefuroxime (cefuroxime (cefuroxime injection) injection) and were reported spontaneously. Data are generally insufficient to allow an estimate of incidence or to establish causation.
Cephalosporin-class Adverse Reactions: In addition to the adverse reactions listed above that have been observed in patients treated with cefuroxime (cefuroxime (cefuroxime injection) injection) , the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:
Adverse Reactions: Vomiting, abdominal pain, colitis, vaginitis including vaginal candidiasis, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, and hemorrhage.
Several cephalosporins, including cefuroxime (cefuroxime (cefuroxime injection) injection) , have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see DOSAGE AND ADMINISTRATION). If seizures associated with drug therapy should occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Read the entire FDA prescribing information for Cefuroxime (Cefuroxime Injection)
Additional Cefuroxime Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.